论文部分内容阅读
澳大利亚沃尔特与伊丽莎·霍尔医学研究所科学家最近发现通过抑制致癌蛋白MYC,可治疗由该致癌蛋白引发的淋巴癌。相关论文发表在本周《基因与发育》杂志上。该研究负责人吉玛·凯利博士称,灭活MCL-1蛋白,能杀死有高水平MYC的淋巴瘤细胞。这表明未来通过遏制MCL-1能有效治疗MYC表达水平高的癌症,而其不良反应对体内正常细胞来说是可以承受的。(源自:药品资讯网)
Researchers at Walter and Elizabeth Hall Medical Institute in Australia have recently found that lymphoma induced by this oncoprotein can be treated by inhibiting the oncogenic protein MYC. Related papers published in this week’s “Gene and Development” magazine. Lead researcher Dr. Ji Ma Kelly said inactivating MCL-1 protein can kill lymphoma cells with high levels of MYC. This indicates that in future, MCL-1 can effectively treat cancers with high MYC expression level while its adverse reactions are tolerable to normal cells in vivo. (From: Drug Information Network)